研究目的
To investigate the utility of porphyrin-based compounds in PET/fluorescence imaging and photodynamic therapy, and to develop a multifunctional nanoplatform for tumor-imaging and therapy.
研究成果
The study demonstrates the utility of a biodegradable/biocompatible, nontoxic PAA-based nanoparticles-photosensitizer formulation for developing a highly efficient 'Multimodality Platform' for tumor-imaging by PET/Fluorescence and photodynamic therapy. The PAA NPs formulation significantly changes the pharmacokinetic profile of the PET and PDT agents, providing an efficient approach to improve the drug delivery of various hydrophobic cancer therapeutic agents.
研究不足
The study was limited to BALB/c mice bearing Colon26 tumors, and the translation of findings to human clinical applications requires further investigation. The study also highlights the need for GMP manufacturing of nanoparticles for clinical trials.
1：Experimental Design and Method Selection:
The study involved the synthesis and evaluation of a series of 124I-labeled compounds related to pyropheophorbide-a and purpurinimides derived from chlorophyll-a. The non-toxic polyacrylamide (PAA) nanoparticles were used to enhance the pharmacokinetic profile of the photosensitizer.
2：Sample Selection and Data Sources:
BALB/c mice bearing Colon26 tumors were used for in vivo studies.
3：List of Experimental Equipment and Materials:
The study utilized a Nicomp 370 Submicron Particle Analyzer for size measurement, SEM for morphology, and a Fluorolog-3 spectrofluorometer for fluorescence spectra.
4：Experimental Procedures and Operational Workflow:
The photosensitizer was post-loaded into PAA nanoparticles, and the formulation was characterized by NMR, DLS, and SEM. In vivo imaging and biodistribution studies were performed.
5：Data Analysis Methods:
The data were analyzed using Microsoft Excel for statistical analysis, and AMIDE software for PET image analysis.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
